A typical method to enhance the efficacy using combination therapy involves blocking the antibodies against two key immune checkpoints, cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and PD-1, thereby resulting in higher response rates to the treatment and improvements in the survival of patients with metastatic melanoma (151). This evidence concerns the gene CTLA4 and metastatic melanoma.